Skip to main content
Springer logoLink to Springer
. 2016 Nov 10;21(3):523. doi: 10.1007/s10157-016-1350-0

Erratum to: Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study

Fumihiko Koiwa 1,, Akira Terao 2
PMCID: PMC6828107  PMID: 27832343

Erratum to: Clin Exp Nephrol DOI 10.1007/s10157-016-1299-z

In the original publication of this paper, the second sentence of Fig. 3 is incorrectly published as:

The mean serum phosphorus levels were significantly higher in all the PA21 groups in all the time-points after administering the PA21 dose (all P < 0.001, one-sample t test).

The corrected sentence is given below:

The mean serum phosphorus levels were significantly lower in all the PA21 groups at all the time-points after administering the PA21 dose (all P < 0.001, one-sample t test).

Footnotes

The online version of the original article can be found under doi:10.1007/s10157-016-1299-z.


Articles from Clinical and Experimental Nephrology are provided here courtesy of Springer

RESOURCES